Abeona Therapeutics Inc vs Byrna Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Byrna Technologies Inc trades at $4.68 (market cap $106.74M). The key difference: Abeona Therapeutics Inc is far larger — about 3.9× Byrna Technologies Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BYRN | |
|---|---|---|
Market Cap | $421.19M | $106.74M |
Sector | Health | Technology |
52-Week High | $7.45 | $27.63 |
52-Week Low | $4.17 | $3.18 |
Enterprise Value | $276.10M | $98.35M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BYRN trades at $4.45, up 2.06% today, but faces bearish technical signals and recent earnings challenges. The company reported a Q2 2026 loss of $0.44 per share, missing estimates, with revenue declining 42.5% year-over-year. Despite a 71.4% analyst buy rating, negative net income margin and cash flow concerns highlight operational headwinds. Recent management appointments aim to revitalize marketing and retail growth.
Outlook remains cautious due to weak sales trends and profitability issues, though strategic hires and acquisitions could support a turnaround. Key risks include sustained revenue declines and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →